An observational study in Atrial Fibrillation, sponsored by China National Center for Cardiovascular Diseases. Not yet recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2025-06-29.
Sponsored by China National Center for Cardiovascular Diseases · Observational
This study aims to integrate multi-omics data (genomics, imaging, serology, etc.) to achieve precise phenotyping classification for atrial fibrillation (AF) patients and explore personalized rhythm control strategies. By enrolling over 1,000 AF patients, we will collect genomic data including GWAS and single-cell sequencing, combined with cardiac MRI, CT, echocardiography imaging, and serum biomarkers, to uncover AF pathological mechanisms and recurrence risks at molecular and structural levels. Machine learning and AI algorithms will be employed to develop AF phenotypic classification models, which will be validated across multiple centers to assess their accuracy and reliability in predicting AF recurrence and therapeutic responses. Furthermore, clinical trials will evaluate the efficacy of oral dronedarone hydrochloride tablets and intravenous nicorandil hydrochloride in preventing post-catheter ablation recurrence and their safety/effectiveness in early cardioversion. Finally, based on advanced phenotyping results, we will establish personalized rhythm control strategies integrating pharmacotherapy, catheter ablation, and lifestyle interventions to optimize AF management.
3,869 studies on the registry are indexed under Atrial Fibrillation; 923 are open to participants now.
This study's planned enrollment of 1,000 is above the median of 300 across 1,362 observational studies indexed under Atrial Fibrillation.
Browse Atrial Fibrillation studies →China National Center for Cardiovascular Diseases is the lead sponsor of 256 studies on the registry; 134 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients diagnosed with atrial fibrillation.
Inclusion Criteria:
Patients with atrial fibrillation
Recurrence of atrial arrhythmia
Atrial arrhythmia events lasting more than 30 seconds within 3 months to 1 year after catheter ablation of atrial fibrillation.
Time frame: 1 year after catheter ablation of atrial fibrillation.
Plan to share: Undecided
This study is not yet recruiting, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
China National Center for Cardiovascular Diseases